Invicta Animal Health has launched a licensed synthetic sodium hyaluronate, for intra-articular treatment of lameness caused by joint dysfunction associated with non-infectious synovitis in horses.

Invicta Animal Health has launched a licensed synthetic sodium hyaluronate (HA), for intra-articular treatment of lameness caused by joint dysfunction associated with non-infectious synovitis in horses.

Invicta Animal Health's first POM-V, SynVet-50.SynVet-50 is Invicta’s first POM-V product.

According to the company, the functional mechanisms of HA are directly dependent on the molecular weight and concentration of HA. Therefore, SynVet-50 has been formulated with a molecular weight of 1.5m Daltons – the highest of any synthetic HA available in the UK.

Additionally, at 20mg per ml, SynVet-50 is also the most concentrated HA available.  

SynVet-50 is a 2.5ml solution containing 50mg HA, conveniently presented in a 5ml glass syringe. Storage is at ambient temperature so the product is not subject to refrigerated storage.

Invicta managing director Rob Watkins said: “We are excited to be launching our first licensed medicine in the UK. The management team of Invicta has more than 10 years experience in this market which has allowed us to provide a product strongly focused on the clinicians’ needs, not just in terms of technical ability, but also in convenience of presentation.”

View your activity >

Leave a Reply

Be the First to Comment!

Notify of
avatar

wpDiscuz